ABINGDON, England, April 26, 2018 /PRNewswire/ --
OBN (UK) Ltd, the Membership organisation that supports the life sciences industry in the UK, announces today that BioTrinity, its annual conference and 12th edition, has once again confirmed its position as one of Europe's leading biopartnering and investment conferences.
John Harris, CEO of OBN, said: "This year's BioTrinity 2018 has proven a huge success once again. We are gratified with the number of senior-level attendees, specialist investors and extremely high calibre panellists, as well as the continued strong attendance of senior pharma professionals. We continually strive to convene the right audience and deliver a high-quality experience across all aspects of the conference, including the exhibition, partnering and networking sessions as well as the new and improved BioLaunchPad which was well received by companies and investors."
The success of BioTrinity 2018 as one of Europe's key life sciences investment and biopartnering conference is reflected by:
About OBN
OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 400 member companies are located across the Golden Triangle and beyond to, Birmingham, Nottingham, Manchester, the North East and Scotland, all benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is also known for its delivery of BioTrinity (13th edition: 29 April - 1 May 2019), Europe's leading life sciences investment and biopartnering conference taking place in London.
Further information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website www.obn.org.uk
Contacts: Event enquiries and picture requests: Jane O'Driscoll, Head of Events, OBN: [email protected] Communications enquiries: Georgia Fogden-King Communications Manager OBN: [email protected]
SOURCE OBN
Advertisement
Leading
annual
life
sciences
event
attracted
more
than
160 CEOs and 150
investors
and
delegates from
more
than
50
pharmaceutical
companies
Advertisement
OBN (UK) Ltd, the Membership organisation that supports the life sciences industry in the UK, announces today that BioTrinity, its annual conference and 12th edition, has once again confirmed its position as one of Europe's leading biopartnering and investment conferences.
John Harris, CEO of OBN, said: "This year's BioTrinity 2018 has proven a huge success once again. We are gratified with the number of senior-level attendees, specialist investors and extremely high calibre panellists, as well as the continued strong attendance of senior pharma professionals. We continually strive to convene the right audience and deliver a high-quality experience across all aspects of the conference, including the exhibition, partnering and networking sessions as well as the new and improved BioLaunchPad which was well received by companies and investors."
The success of BioTrinity 2018 as one of Europe's key life sciences investment and biopartnering conference is reflected by:
- Up to 800 delegates attended from over 600 companies from more than 25 countries across Europe, Asia, Australasia and North America
- Participation of more than 150 investors specialising in funding emerging biotechnology and life science companies as well as delegates from more than 50 pharmaceutical companies
- A packed agenda of panel discussions and keynotes, including speakers such as Jim Al-Khalili, Broadcaster and Quantum Physicist who spoke on 'What science can tell us about our future'
- Close to 45 companies (comprising biotech, medtech and digital healthcare) presented at BioLaunchPad, BioTrinity's refreshed company showcase platform
- More than 2000 one-to-one partnering meetings took place throughout the conference
- Another successful Perfect Pitch competition, won this year by Cambridge Respiratory Innovations' CEO, Jeremy Walsh
About OBN
OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 400 member companies are located across the Golden Triangle and beyond to, Birmingham, Nottingham, Manchester, the North East and Scotland, all benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is also known for its delivery of BioTrinity (13th edition: 29 April - 1 May 2019), Europe's leading life sciences investment and biopartnering conference taking place in London.
Further information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website www.obn.org.uk
Contacts: Event enquiries and picture requests: Jane O'Driscoll, Head of Events, OBN: [email protected] Communications enquiries: Georgia Fogden-King Communications Manager OBN: [email protected]
SOURCE OBN
